About our Instructors:
Jeffrey Crawford, MD
Jeffrey Crawford is the George Barth Professor for Research in Cancer and Chief of Medical Oncology in the Department of Medicine at the Duke University Medical Center. Dr. Crawford earned his medical degree at Ohio State University, USA. He was an Intern, Junior and Senior Assistant Resident in Medicine, and a Hematology/Oncology fellow at Duke University. Dr. Crawford later became Chief Resident in Medicine at
Duke University/Veteran’s Administration Medical Center, and also a Geriatric Fellow. He is board certified in Internal Medicine as well as in the Hematology and Oncology subspecialties.
Dr. Crawford’s research interests include new treatment approaches in lung cancer, supportive cancer therapies and clinical trials of hematopoietic growth factors, biological agents and targeted drug development. He has led many US trial investigations on various cancer drugs, several of which have resulted in FDA approval. He also holds several positions with the National Comprehensive Cancer Network (NCCN), including chair of the Myeloid Growth Factor Committee and member of the Clinical Trials Network Investigator Steering Committee. Dr. Crawford is vice-chair of the respiratory committee of the Cancer and Leukemia Group B (CALGB) and is Principal Investigator in the CALGB for Duke. Dr. Crawford is the Principal Investigator for the Cancer Biology and Research T32 training grant at Duke. He has served multiple leadership roles in the American Society of Clinical Oncology (ASCO), the Multinational Association of Supportive Care (MASCC), Advisor of the Chinese Geriatric Oncology Society and is a member of the Curriculum Planning Executive Committee of the International Association for Study of Lung Cancer (IASLC).
He is a steering committee member of the Awareness of Neutropenia in Chemotherapy (ANC) Study Group. This group has been instrumental in the development and analysis of the largest prospective study of chemotherapy delivery in the United States. Dr. Crawford has authored or co-authored 145 scientific articles, 60 book chapters and reviews, 180 abstracts and is co-editor of the book “Cancer Supportive Care.” He serves on the editorial boards of several journals. Dr. Crawford has received the Outstanding Service Award, Cancer Care, Inc, NY, America’s Top Doctors Award, Castle Connolly Medical Ltd, the Wayne Rundles Award for Excellence in Clinical Research, the Joseph Greenfield Research Faculty Award and the Wendell Rosse Teaching Award.
Nancy Dawson, MD
Dr. Nancy A. Dawson is the William M. Scholl Professor of Medicine and Oncology, Director of the Clinical Research Management Office and Director of Clinical Research in the Prostate Cancer Research Center at the Lombardi Comprehensive Cancer Center at Georgetown University. Previously she was the Director of Genito-Urinary Medical Oncology at the University of Maryland Greenebaum Cancer Center from 1999
Dr. Dawson retired as a colonel in the United States Army in June, 1999. She served her entire military career at Walter Reed Army Medical Center where she was Director of Clinical Research, Chief of Hematology-Oncology Service, and Consultant to the Surgeon General of the Army. She was also a senior investigator in the signal Transduction and Oncogenesis Section of the Medical Branch of the National Cancer Institute.
She served as the Vice-Chair of the Prostate Committee for the Cancer and Leukemia Group B (CALGB) for a decade and has chaired several CALGB studies for prostate cancer. She is co-editor of Prostate Cancer (1994) and Prostate Cancer: Translational and Emerging Therapies (2006). She is currently focusing on novel systemic approaches to the treatment of prostate, bladder and kidney cancer. Dr. Dawson earned her undergraduate degree from the University of California, Berkeley, and her medical degree, cum laude, from Georgetown University School of Medicine, Washington, D.C.Stergios Moschos
Stergios Moschos is a Clinical Associate Professor of Medicine at the University of North Carolina Chapel Hill. He
received his Medical Degree at the National and Kapodistrian University of Athens, Greece in 1997. He completed his Internal Medicine Residency at the Tufts-affiliated Newton-Wellesley Hospital, in Boston, MA followed by a clinical fellowship in Hematology/Oncology at the University of Pittsburgh Medical Center. He was appointed at the rank of Assistant Professor at the University of Pittsburgh Medical Center in 2005 where he remained an active member of the Melanoma and Skin Cancer Program until 2011. His research –basic, translational, and clinical- is focused on identifying molecules that are important for melanoma development and progression, identifying mechanisms of action of FDA-approved and investigational agents in melanoma. More recently, he participated in the pivotal trials leading to the F.D.A approval of vemurafenib in metastatic melanoma. Currently his research is focused on studying the biology of melanoma brain metastases, the role of metabolism in melanoma, as well as mechanisms of resistance to molecularly targeted therapies.
Bert H. O’Neil, MD
Bert H. O’Neil, MD, is an Associate Professor in the Division of Hematology and Oncology at the University of North Carolina at Chapel Hill. Dr. O’Neil earned his BS in biology at the University of California at Irvine and his MD at the UCLA School of Medicine. After graduating, he completed his residency in internal medicine at the University of California at San Francisco. His fellowship in hematology and oncology was also conducted at the University of California at San Francisco.
Currently, Dr. O’Neil serves as the Medical Director of the UNC Cancer Clinical Trials Protocol Office, Director of the Gastrointestinal Cancer Research Program at UNC, and the Section Chief of GI malignancies at UNC. He is also a Cadre Member of the CALGB GI Committee and a CALGB Study Chair. Dr. O’Neil’s research interests include elucidation of novel mechanisms of resistance to radiation therapy in rectal cancer, and early drug development for gastrointestinal malignancies, particularly colorectal cancer and hepatocellular carcinoma.Jeffrey Peppercorn
Dr. Peppercorn is a hematologist/oncologist with special interests in breast cancer, medical ethics, and trial accrual. He trained at Harvard Medical School, completed internal medicine residency at Massachusetts General Hospital, and completed his hematology/oncology fellowship training at the Dana-Farber Cancer Institute. His clinical specialty is breast cancer and he is currently an Assistant Professor of Medicine at Duke University. He also co-chairs the CALGB ethics committee. His research ranges from clinical trials of novel therapeutics for breast cancer to studies of accrual to clinical trials and medical ethics and he is the author of numerous publications, reviews, and chapters on these topics.
1. Peppercorn J, Partridge AH. Breast Cancer in Young Women: A New Color or a Different Shade of Pink? J Clin Oncol. In Press. 2008
2. Peppercorn J, Buss WG, Fost N, Godley PA. The Dilemma of Data Safety Monitoring: Providing Significant New Data to Research Subject. Lancet. 2008 February 9: 371: 527-529
3. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008 Feb; 26 (1): 1-10.
4. Peppercorn J, Carey L. Genotype-Guided Adjuvant Endocrine Therapy: New Tricks from an Old Drug? Expert Rev Anticancer Ther. 2008 Feb;8(2):191-4.
5. Peppercorn J, Carey L. Updates in Adjuvant Therapy for Breast Cancer in Disease of the Breast. Ed. Harris, JR, Lippman, M, Morrow, M, Osborne, C. Lippincott Williams and Wilkins. 8 (1). 2007
6. J. Peppercorn, E. Blood, E. P. Winer, A. H. Partridge. Association between Pharmaceutical Involvement and Outcomes in Breast Cancer Clinical Trials. Cancer, 2007 April 1: 109 (7): 1239-1246
7. Gail Henderson, Larry R. Churchill, Arlene M. Davis, Michele M. Easter, Christine Grady, Steven Joffe, Nancy Kass, Nancy M.P. King, Charles W. Lidz, Franklin G. Miller, Daniel K. Nelson, Jeffrey Peppercorn, Barbra Bluestone Rothschild, Pamela Sankar, Benjamin S. Wilfond, Catherine R. Zimmer. Clinical Trials and Medical Care: Defining the Therapeutic Misconception. PLoS Medicine 2007 Nov 27; 4 (11):e324
8. Peppercorn J, Weeks JC, Cook EF, Joffe S. Comparing Outcomes Among Cancer Patients Treated Within And Outside Clinical Trials: A Conceptual Framework And Structured Review. Lancet. 2004 Jan 24;363(9405):263-70.
9. Peppercorn J. Management of Metastatic Breast Cancer. Hospital Physician Oncology Board Review Manual. Wayne (PA): Turner White Communications; 2006; 8 (3): 1-12.
10. Peppercorn J, Partridge A, Burstein H, Winer E. Standards For Follow-up Care of Patients with Breast Cancer. Breast 2005 Nov 7;14(6):500-508
250 First Avenue Suite 300Needham, MA 02494P: 781.972.5400F: 781.972.5425E: email@example.com
biological therapeutic productsbiomarkers & diagnosticsbiopharma strategybioprocess & manufacturingchemistryclinical trials & translational medicinedrug & device safety
drug discovery & developmentdrug targetsgenomicshealthcareit & informaticstechnology & tools for life sciencetherapeutic indications
conferencesreportsbarnett educational servicesconsultingpublications & eNewslettersprofessional services
executive teamtestimonialschi timelinemailing listcareers